Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04151342

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Sponsor: University Health Network, Toronto

View on ClinicalTrials.gov

Summary

This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

5500

Start Date

2020-01-17

Completion Date

2029-12

Last Updated

2025-12-03

Healthy Volunteers

No

Interventions

DRUG

Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.

Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.

OTHER

Patient-reported outcomes (PROs)

Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.

Locations (27)

Tom Baker Cancer Centre - University of Calgary - Alberta Health Services

Calgary, Alberta, Canada

Cross Cancer Institute, University of Alberta - Alberta Health Services

Edmonton, Alberta, Canada

BC Cancer

Vancouver, British Columbia, Canada

CancerCare Manitoba/University of Manitoba

Winnipeg, Manitoba, Canada

Dr. Everett Chalmers Regional Hospital

Fredericton, New Brunswick, Canada

Dr. H. Bliss Murphy Cancer Centre

St. John's, Newfoundland and Labrador, Canada

Queen Elizabeth II (QEII) Health Sciences Centre

Halifax, Nova Scotia, Canada

William Osler Health System - Brampton Civic Hospital

Brampton, Ontario, Canada

Health Sciences North

Greater Sudbury, Ontario, Canada

Hamilton Health Sciences - Juravinski Cancer Centre

Hamilton, Ontario, Canada

Kingston Health Sciences Centre (KHSC)

Kingston, Ontario, Canada

Lawson Health Research Institute - London Health Sciences Centre

London, Ontario, Canada

Ottawa Hospital Cancer Centre

Ottawa, Ontario, Canada

Thunder Bay Regional Health Sciences Centre

Thunder Bay, Ontario, Canada

Princess Margaret Cancer Centre (PMCC) - University Health Network (UHN)

Toronto, Ontario, Canada

Mount Sinai Hospital

Toronto, Ontario, Canada

Sunnybrook Research Institute - Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Centre hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, Canada

Hôpital du Sacré-Coeur-de-Montréal (HSCM)

Montreal, Quebec, Canada

Jewish General Hospital

Montreal, Quebec, Canada

McGill University Health Centre

Montreal, Quebec, Canada

St. Mary's Hospital Center

Montreal, Quebec, Canada

Centre hospitalier de l'université de Québec - Université Laval

Québec, Quebec, Canada

Institut Universitaire de Cardiologie et de Pneumologie de Québec

Québec, Quebec, Canada

Centre hospitalier universitaire de Sherbrooke (CHUS)

Sherbrooke, Quebec, Canada

Allan Blair Cancer Centre

Regina, Saskatchewan, Canada

Saskatoon Cancer Centre

Saskatoon, Saskatchewan, Canada